Forte Biosciences shares to be delisted from Nasdaq after exchange filing

What happened

Forte Biosciences, Inc. (Nasdaq: FBRX), a pharmaceutical company based in Dallas, Texas, is having its common stock removed from listing and registration on the Nasdaq Stock Market. On August 27, 2026, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission (SEC) to strike the shares from the exchange.

The filing indicates the delisting is being done under SEC Rule 12d2-2(c), which governs voluntary withdrawal of a security from listing by the issuer. That means Forte Biosciences itself initiated the removal, and the company complied with Nasdaq's rules for doing so.

The company's stock closed at $48.93 on August 27, up 8.76% from the previous close of $44.99. The filing does not explain why the company chose to delist or what it plans to do next.

About the company

Forte Biosciences is a pharmaceutical preparations company. According to its corporate address and the filing, its principal executive offices are located at 3060 Pegasus Park Dr., Building 6, Dallas, Texas. The stock trades under the ticker FBRX.

The filing does not provide details about the company's drug pipeline, revenue, or reasons for the delisting.

What this means

A Form 25 is the notification a national securities exchange files with the SEC when a security is removed from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. Here, Nasdaq filed the form on behalf of Forte Biosciences' common stock.

The form allows delisting under several rule provisions. In this case, the box for Rule 12d2-2(c) is marked, which means the issuer requested the delisting voluntarily. Under this rule, the issuer must have followed its exchange's procedures, and Nasdaq certified it had reasonable grounds to believe the requirements were met.

For shareholders, a delisting means the shares will no longer trade on Nasdaq. The stock could move to another exchange or to over-the-counter markets, but the filing does not say where, if anywhere, the shares will trade next. The 8.8% price rise on the filing date is not explained by the filing. Investors should understand that delisting often reduces liquidity, but this filing alone does not specify what will happen to the shares.

The filing is signed by Tara Petta, an Assistant Vice President at Nasdaq, and is dated August 27, 2026. It does not give a date when the delisting becomes effective or describe any future corporate actions.